



PostedApprovedLabeling-Text.pdf

18. Krystal AD, Huang H, Zummo J, et al. A WASO sub-group analysis of a 6-month study of eszopiclone 3 mg. *Sleep Med* 2012; 13: 691–696.

19. Rozerem (ramelteon tablets) prescribing information. Deerfield, Illinois: Takeda Pharmaceuticals America Inc.; 2010. Dostupné na: <http://general.takedapharm.com/content/file.aspx?filetypecode=rozerempi&cacheRandomizer=15ac1dc2-362c-4f72-b98a-5a334d7a2545>

20. Almeida Montes LG, Ontiveros Uribe MP, Cortés Sotres J, et al. Treatment of primary insomnia with melatonin: a double-blind, placebo-controlled, crossover study. *J Psychiatry Neurosci* 2003; 28: 191–196.

21. Roth T, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. *Sleep*. 2007; 30: 1555–1561.

22. Silenor (doxepin tablets) prescribing information. Morristown, New Jersey: Pernix Therapeutics; 2010. Dostupné na: <https://www.silenor.com/Content/pdf/prescribing-information.pdf>

23. Yeung WF, Chung KF, Yung KP, Ng TH. Doxepin for insomnia: a systematic review of randomized placebo-controlled trials. *Sleep Med Rev* 2015; 19: 75–83.

24. Food and Drug Administration FDA approves new type of sleep drug, Belsomra. Dostupné na: <http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm409950.htm>

25. Belsomra (suvorexant tablets) prescribing information. White-house Station, New Jersey: Merck & Co., Inc. Dostupné na: https://www.merck.com/product/usa/pi_circulars/b/belsomra/belsomra_pi.pdf